AmgenvsZevra Therapeutics

AMGN and ZVRA stock compared: price, dividend, valuation and results, from SEC filings.

AMGN

Amgen Inc.

$435.64

Value $235B

-0.72%
AMGN's page

ZVRA

Zevra Therapeutics, Inc.

$8.76

Value $514M

-3.42%
ZVRA's page

Amgen (AMGN) has a market value of $235B and Zevra Therapeutics (ZVRA) $514M. Over the last year, with dividends, AMGN moved +30.7% and ZVRA -9.5%. The P/E is 25.0 for AMGN and 6.7 for ZVRA. Dividend yield: AMGN 2.28%, ZVRA none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    AMGN$235B

    ZVRA$514M

    AMGN is 457 times ZVRA

  • Revenue, 12 months

    AMGN$38.9B

    ZVRA$148M

    AMGN is 263 times ZVRA

  • Net income, 12 months

    AMGN$9.4B

    ZVRA$78M

    AMGN is 120 times ZVRA

  • Operating margin

    AMGN32.4%

    ZVRA60.8%

    28.4 points apart

  • ROIC

    AMGN16.2%

    ZVRA36.3%

    20.1 points apart

  • P/E

    AMGN25.0

    ZVRA6.7

    AMGN is 3.7 times ZVRA

  • Dividend yield

    AMGN2.3%

    ZVRA0.0%

    2.3 points apart

  • 5-year return

    AMGN+144.9%

    ZVRA+4.3%

    140.6 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

AMGN+144.9%

ZVRA+4.3%

10020020222023202420252026
Returns by period
PeriodAMGNWith dividendsZVRAWith dividends
1 year since November 19, 2025+30.7%Price +27.2%-9.5%Price -9.5%
3 years since November 20, 2023+78.2%+21.2% a yearPrice +64.2%+95.5%+25.0% a yearPrice +95.5%
5 years since November 19, 2021+144.9%+19.6% a yearPrice +111.4%+4.3%+0.8% a yearPrice +4.3%
10 years since November 21, 2016+300.4%+14.9% a yearPrice +199.3%-86.6%-18.2% a yearPrice -86.6%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

AMGNAmgenZVRAZevra Therapeutics

Valuation

AMGNZVRA
Valuation
Price$435.64$8.76
Market value$235B$514M
Enterprise value (EV)$276B$319M
P/E25.06.7
P/E, 5-year median23.0–
P/B16.42.2
EV/EBIT21.93.6
Free cash flow yield4.1%7.4%

Results and growth

AMGNZVRA
Results and growth
Revenue, 12 months$38.9B$148M
Net income, 12 months$9.4B$78M
Free cash flow, 12 months$9.6B$38M
Earnings per share, 12 months$17.25$1.19
Revenue growth, year on year10.0%350.9%
Revenue growth a year, past+7.6%over 5 years+51.6%over 5 years
EPS growth a year, past+2.9%over 5 years–

Margins and returns on capital

AMGNZVRA
Margins and returns on capital
Gross margin70.9%95.4%
Operating margin32.4%60.8%
Net margin24.1%52.8%
ROIC16.2%36.3%
ROE87.8%41.1%

Balance sheet

AMGNZVRA
Balance sheet
Cash$13.2B$196M
Total debt$54.0B$1.2M
Net debt / EBITDA2.3-2.1
Interest cover4.8×24.6×

Dividends and buybacks

AMGNZVRA
Dividends and buybacks
Dividend yield2.3%–
Dividend per share, 12 months$9.94–
Dividend growth a year, past+8.1%over 5 years–
Buyback yield––
Shareholder yield2.3%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: AMGN or ZVRA

Didn't find what you were looking for?

Ask us
Which is bigger, Amgen or Zevra Therapeutics?

By market value, Amgen ($235B) is about 456.6 times Zevra Therapeutics ($514M), at today's prices.

How did AMGN and ZVRA stock do over the last 10 years?

Since November 21, 2016, AMGN's price moved +199.3% and ZVRA's -86.6%. With dividends: AMGN +300.4% (+14.9% a year), ZVRA -86.6% (-18.2% a year). Past returns do not predict future ones.

Which pays the higher dividend, AMGN or ZVRA?

The dividend yield at today's price is 2.28% for Amgen and none for Zevra Therapeutics. Over the last twelve months they paid $9.94 and – per share.

What is the P/E of AMGN and ZVRA?

At today's price, the P/E is 25.0 for AMGN and 6.7 for ZVRA. It is the share price over the last twelve months' earnings per share.

Which has the higher profit margins, Amgen or Zevra Therapeutics?

Over the last twelve months, the net margin was 24.1% for Amgen and 52.8% for Zevra Therapeutics, and the operating margin 32.4% and 60.8%. Revenue was $38.9B and $148M.

Which is the better investment, Amgen or Zevra Therapeutics?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.